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 26 
ABSTRACT  27 
The glucagon-like peptide 1 (GLP-1) analogue, liraglutide, is a GLP-1 agonist and is used in 28 
the treatment of type 2 diabetes mellitus and obesity. From a pharmaceutical perspective, it is 29 
important to know the oligomerization state of liraglutide with respect to stability. Compared 30 
to GLP-1, liraglutide has an added fatty acid (FA) moiety that causes oligomerization of 31 
liraglutide as suggested by small-angle X-ray scattering (SAXS) and multi angle static light 32 
scattering (MALS) results. SAXS data suggested a global shape of a hollow elliptical 33 
cylinder of size hexa-, hepta or octamer, whereas MALS data indicate a hexamer. To 34 
elaborate and further the explanation of the stability of these oligomers and the role of the FA 35 
chains, a series of molecular dynamics simulations were carried out on 11 different hexa-, 36 
hepta- and octameric systems. Our results indicate that interactions of the fatty acid chains 37 
contribute noticeably to the stabilization. The simulation results indicate that the heptamer 38 
with paired FA chains is the most stable oligomer when compared to the 10 other 39 
investigated structures. In agreement with the SAXS data, the heptamer forms a water-filled 40 
oligomer of elliptical cylindrical shape. Theoretical SAXS curves extracted from the 41 
simulations qualitatively agree with the experimentally determined SAXS curves supporting 42 
the view that liraglutide forms heptamers in solution. 43 
  44 
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INTRODUCTION 45 
The glucagon-like peptide 1 (GLP-1) receptor is a well-established therapeutic target for the 46 
treatment of type 2 diabetes mellitus (T2DM) (1–3), and extensive research has established 47 
the physiologic roles of GLP-1 and its endogenous receptor in regulating glucose homeostasis 48 
and energy metabolism (4, 5). GLP-1-(7-37) is a 31 amino acid incretin hormone secreted by 49 
the endocrine L cells in the gut wall upon glucose intake (6), and is secreted in response to 50 
the nutrient content of the gastrointestinal tract and thus potentiate insulin exocytosis from 51 
pancreatic β-cells in a glucose-dependent manner (6, 7). Additionally, GLP-1 suppresses 52 
appetite, glucagon secretion, and gastric emptying, all of which contribute to inhibition of the 53 
postprandial rise in plasma glucose concentrations (8). GLP-1 is responsible for up to 60 % of 54 
the postprandial insulin response (9). Recent studies show that GLP-1 is not only a key factor 55 
in T2DM treatment, but also has potential in the treatment of obesity (1, 10) and has shown 56 
positive effects on neuroprotection in animal models (11), which can potentially be used for 57 
the treatment of Parkinson’s and Alzheimer’s disease (12–15). 58 
While GLP-1 is interesting for a pharmaceutical application, it cannot be used for routine 59 
treatment, since its biological half-life is only a few minutes (16, 17). The short insulinotropic 60 
action of GLP-1 results from the degradation of the peptide by dipeptidyl-peptidase IV (DPP 61 
IV) and rapid renal clearance due to its relatively small size (18–20). DPP IV degrades GLP-62 
1 at the N-terminus by cleaving off the first two amino acids, generating the biologically 63 
inactive fragment, GLP-1-(9-37) (9, 21). To overcome this shortcoming, different strategies 64 
have been used. Those include: i) incorporation of the peptides in injectable microspheres; ii) 65 
fusion with larger carrier molecules like albumin or fragment crystallizable region of 66 
immunoglobulin G or polyethylene glycol; iii) attachment of a fatty acid (FA) directing 67 
oligomerization and promoting reversible binding to endogenous human serum albumin 68 
(HSA) (20). All three approaches result in an increased half-life partly due to the increased 69 
size of the drug minimizing the renal clearance mechanism. The latter approach, for instance, 70 
has been utilized in designing the GLP-1 analogue: liraglutide (Victoza®, Novo Nordisk 71 
A/S) (22, 23). An in depth understanding of the oligomerization state of liraglutide is not only 72 
instrumental in the understanding of the increased half-life observed for this molecule but 73 
also to ensure a stable oligomeric state, since uncontrolled and extensive oligomerization can 74 
drive fibrillation (24). As shown in Fig. 1, liraglutide, a C-16 acyl chain (palmitoyl) is linked 75 
to Lys26 via a γ-glutamic acid spacer, and the lysine in position 34 of the native GLP-1 76 
sequence is exchanged with arginine to ensure homogenous palmitoylation at position 26 (25, 77 
26). The general understanding is that the acyl chain allows a non-covalent binding to 78 
albumin, which delays both proteolytic inactivation by DPP-IV and renal clearance, resulting 79 
in a biological half-life of about 13-14 hours and allowing once-daily administration (2, 23). 80 
A further prolongation may also be caused by the fatty acid chain that may sterically hinder 81 
DPP IV from degrading liraglutide (5). Furthermore, studies have shown that one way to 82 
stabilize GLP-1 is to add a clustering agent that causes the peptide to oligomerize (2), thus, 83 
the FA chain in liraglutide could act as a clustering agent. 84 
Although the pharmacological efficiency of liraglutide has been established (23, 27), there is 85 
a lack of a molecular understanding of the solution structure of liraglutide. Using analytical 86 
ultracentrifugation, Steensgaard and co-workers could show that liraglutide oligomerizes in a 87 
concentration independent manner forming predominately heptamers in the concentration 88 
range of 0.004–4.501 mg/mL (28). Recently, Wang and co-workers studied the pH 89 
dependence of the size and secondary structure of liraglutide oligomers using light-scattering 90 
and circular dichroism, respectively (29). The authors report a transformation from an 91 
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octamer to a dodecamer at pH 6.4 and 6.9 with subsequent partial loss of the α-helical 92 
structure of liraglutide. Furthermore, it has been shown that the oligomerization of GLP-1 93 
and similar peptide analogues is dependent on the pH and ionic strength (30), and thus 94 
different solution structures may exist (3, 31). 95 
In order to get further insight in the solution structure of liraglutide, we have performed a 96 
series of molecular dynamics (MD) simulations, and simulation results are compared with 97 
results from small angle X-ray scattering (SAXS) and multi angle static light scattering 98 
(MALS) experiments. 99 
  100 
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MATERIAL AND METHODS 101 
SAXS: 3 ml commercial Victoza® (contains 18 mg liraglutide (free-base, anhydrous) and the 102 
following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 103 
mg; phenol, 5.5 mg in aqueous solution (32)) was dialyzed against 3×1 L buffer containing 104 
approximately 0.47 mg/mL (0.376 mM) Na2HPO4•2H2O, pH 8.1, over 3 days. Concentration 105 
determinations were performed with the NanoDrop® 1000 Spectrophotometer from Thermo 106 
Scientific at 280 nm. The extinction coefficient was calculated to be 6990 cm-1M-1 with the 107 
ProtParam (33) tool from ExPASy.org (34) using the primary sequence of the protein.  108 
SAXS measurements were performed at the MAX IV laboratories at beamline I911-SAXS, 109 
Sweden (35). The sample detector distance and the direct beam position was calibrated using 110 
silver behenate (AgBe). Parameters are shown in Table S2 in the Supporting Material. 111 
Measurements on pure water were used to get the data on an absolute scale. Buffers were 112 
measured both before and after each sample and averaged before subtraction. The sample size 113 
was approximately 50 µL injected manually in a flow cell. Measurements were performed on 114 
a series of liraglutide samples at approximate concentrations: 1 mg/mL, 2 mg/mL, and 115 
4.7 mg/mL.  116 
All calibrations and corrections of the SAXS data were done using the in-house software 117 
Bli911-4 (35). Buffer averaging and subsequent subtraction prior to data analysis was done in 118 
Primus (36). The ATSAS program package version 2.4 (37) was used for further data 119 
analysis. Evaluation of the Guinier region was performed within Primus. The pair distribution 120 
function, p(r), was evaluated using the interactive program Gnom (38). 121 
AF4-UV-MALS: Asymmetric flow field flow fractionation (AF4) separation was performed 122 
using a Dionex, Thermo Scientific UltiMate 3000 autosampler and pump (Thermo Fisher 123 
Scientific Inc., Waltham, MA, USA) connected to a Wyatt Eclipse AF4 separation system 124 
(Wyatt Technology Europe Gmbh, Dernbach, Germany) followed by a Dionex, Thermo 125 
Scientific UltiMate 3000 RS variable wavelength UV detector set at 280 nm and a Wyatt 126 
Dawn Heleos-II 18-angle MALS detector. Separations were performed using a 10 kDa 127 
molecular weight cutoff polyethersulfone (PES) membrane in a 17.5 cm separation channel 128 
with an S-350 µm spacer. Samples were introduced to the channel at 0.2 mL/min and 129 
subsequently focused at the head of the channel at a focus flow rate of 1.5 mL/min. Samples 130 
were eluted over 15 min with a channel flow rate of 1 mL/min and a cross flow gradient of 131 
4.0 to 2.5 mL/min. Undiluted Victoza® (6 mg/mL liraglutide) and 10x diluted Victoza® 132 
(diluted with eluent) was injected and eluted with 20 mM phosphate, 100 mM NaCl, 0.05 % 133 
NaN3, pH 8.1, filtrated through a 0.1 µm filter. Different injection volumes of undiluted and 134 
diluted Victoza® were used, and the resulting mass loads were 6, 12 and 18 µg liraglutide. 135 
The molecular weight of liraglutide was calculated using the Wyatt Astra software version 136 
6.1.2 with dn/dc  = 0.185 mL/g and UV extinction coefficient (280nm) = 6990 cm-1M-1. 137 
Molecular dynamics (MD) simulations: Several orientations and oligomers of liraglutide have 138 
been investigated. All are based on the solution NMR structure of liraglutide (pdb entry: 139 
4APD) obtained from the Protein Data Bank (39). The coordinates from the pdb file were 140 
copied, translated and rotated in a circle with a radius of 20 Å, corresponding to the results 141 
from SAXS experiments. This resulted in several oligomers containing six, seven, or eight 142 
monomers, respectively. A set of oligomers was created where the monomers were oriented 143 
so that two FA chains were paired in the direction of the elliptical cylinder arrangement, 144 
which hereafter will be referred to hexa-, hepta-, and octamer systems (Fig. 2). In the 145 
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heptamer, one monomer was oriented with the FA chain pointing outward of the elliptical 146 
arrangement. 147 
Furthermore, another set of oligomers were created where some of the monomers were 148 
flipped upside down to see if interactions between the C- and N-terminal charges would 149 
stabilize the structures. For this set of oligomers, the hexa- and one octamer were made with 150 
every second monomer flipped upside down. In the case of the heptamer, only the monomer 151 
with the FA chain pointing outward was flipped upside down. Also, another octameric 152 
structure was prepared where every second monomer pair was flipped upside down. These 153 
configurations are hereafter referred to as AA6_3ud, AA7_1ud, AA8_4udp, and AA8_4uds 154 
systems where ‘ud’, ‘p’, and ‘s’are short for upside down, pair, and single, respectively (Fig. 155 
2). To clarify the extent of the stabilizing effect of the FA chain on the structures, another set 156 
of oligomers were created. One oligomer is constructed according to the rotation and 157 
translation of the first heptamer, but it does not contain any FA chains (hereafter referred to 158 
as AA7_glp1 and represented in Fig. 2). Three other oligomers were also created; a hexa-, 159 
hepta-, and octamer where all the monomers are rotated so that the FA chains are pointing 160 
outward of the elliptical arrangement. These will hereafter be referred to as the AA6_FAout, 161 
AA7_FAout, and AA8_FAout systems (Fig. 2). This gives a total of 11 oligomeric structures. 162 
The structures were solvated using the program Solvate from the H. Grubmüller research 163 
group (40). Water molecules were described by the TIP3 water model (41). Next, the systems 164 
were neutralized by adding 3 Na+ ions per monomer. Simulations were performed at an ionic 165 
strength of 0.1 M NaCl (see details in Table 1). All simulations were performed using the 166 
computer program NAMD (42) with the CHARMM36 force field (43). The same simulation 167 
parameters were used as described by Madsen et al. 2011 (44). See Supporting Material for 168 
detailed description. Analyses of the trajectories were carried out in VMD (45). 169 
Table 1: System and simulation details of the 11 oligomeric systems. 
Structure No. of 
atoms 
No. of 
waters 
No. of 
NaCl 
Initial box size 
(Å) 
Simulation time 
(ns) 
Hexamer 140203 45615 86 113×118×115 69 
Heptamer 53774 16665 31 83×88×89 129 
Octamer 136414 44000 83 113×115×115 71 
AA6_3ud 57419 18055 34 91×88×85 34 
AA7_1ud 57090 17769 33 91×87×87 39 
AA8_4udp 54814 16834 32 91×85×85 41 
AA8_4uds 54928 16872 32 91×85×85 43 
AA6_FAout 52289 16247 31 83×90×85 21 
AA7_FAout 53114 16445 31 83×88×89 51 
AA8_FAout 54937 16875 32 83×90×90 21 
AA7_glp1 51729 16131 30 83×87×87 69 
 170 
Theoretical SAXS curves: The program CRYSOL (46), which is part of the ATSAS package 171 
version 2.6 (37), was used to compare the SAXS curves of the structures extracted from the 172 
MD simulations with the experimental measured SAXS curve of the oligomer. CRYSOL 173 
calculates the scattering intensity based on the atomic coordinates of the protein and adds a 174 
hydration layer simplified as a continuous outer envelope (47). 175 
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RESULTS 177 
The following section is structured as follows: First, experimental results from SAXS and 178 
A4F-UV-MALS are presented followed by the computational results. 179 
SAXS: SAXS intensity curves of liraglutide measured at different concentrations are shown in 180 
Fig. 3. Repulsion is observed already at 1 mg/mL while the shape of the curve is consistent 181 
over the concentration range reflecting a similar shape of molecule. This is also reflected in 182 
the Kratky plots shown in Fig. S1 in the Supporting Material. Corresponding pair distribution 183 
functions are provided in Fig. S2. 184 
Table 2 summarizes the extracted data analysis parameters. The radius of gyration (Rg), 185 
maximum particle diameter (Dmax) and I(0)/c show a slight decrease with concentration as 186 
expected from the repulsive behavior. 187 
Table 2: Parameter overview extracted from SAXS measurements. 
Concentration 
mg/mL 
Rg      
Guinier (Å) 
Rg      
p(r) (Å) 
Dmax 
(Å) 
I(0) 
Guinier 
I(0)   
p(r) 
I(0)/c Molecular Weight 
(kDa) 
1 23.1 23.8 82.0 0.021 0.021 0.021 26 
2 21.7 22.3 75.9 0.040 0.041 0.020 25 
4.7 22.2 22.2 74.2 0.096 0.096 0.020 25 
 188 
The partial specific volume, ν, used for calculating the molecular weight is chosen to match 189 
pure protein and is set to the average value of 0.73 cm3/g. To compare the experimental 190 
results with the model structures extracted from the simulations, the experimental data were 191 
extrapolated to q = 0 to avoid inter-particle repulsion. 192 
AF4-UV-MALS: Analysis of liraglutide showed a single peak and a uniform molecular weight 193 
across the peak in all analyses (Fig. 4, left) indicating that repulsive behavior is negligible at 194 
the concentration range found in the detector. The average molecular weight across the peak 195 
was 22 kDa, which corresponds to a hexamer assuming a monomer molecular weight of 3.7 196 
kDa. Undiluted Victoza® (6 mg/mL liraglutide) and 10× diluted Victoza® was analyzed and 197 
different injection volumes were used, which resulted in mass loads of 6, 12 and 18 µg 198 
liraglutide. Liraglutide is diluted during analysis by the eluate, and the resulting liraglutide 199 
concentration was quantified in the eluate passing the UV detector (Fig. 4, right). Peak 200 
liraglutide concentrations of 0.012, 0.024 and 0.036 mg/mL were observed.   201 
Molecular dynamics simulations: Simulations were performed on several sets consisting of 202 
hexa-, hepta-, and octamer oligomers to study the structural arrangement and stability of the 203 
oligomers including the role of the FA in promoting the stability of the oligomers. The last 204 
structures taken from the simulations are shown in Figs. S3, S4, and S5. 205 
Figs. S3, S4, and S5 show that although the internal structures for all 11 oligomers are highly 206 
distorted compared to the start structures (Fig. 2), all of them but AA6_3ud (Fig. S4 a)) 207 
maintain a tunnel-like structure which is, however, more or less flattened and resembling an 208 
elliptical shape.  209 
The solvent accessible surface area of the oligomers seen in Fig. 5, S6, and S7 relates to the 210 
packing of the monomers. 211 
Overall, the packing of the heptamers appears to be more prominent than the octamers 212 
throughout the simulations indicated by the lower SASA. The AA6_3ud structure has a 213 
significant lower packing than the AA7_1ud, AA8_4udp, and AA8_4uds structures, which 214 
most likely is a result of a complete opening of the elliptical structure as seen in Fig S4 a). 215 
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The relatively high SASA for the AA6_FAout oligomer could be due to the elongation of 216 
some of the monomers which appear to unfold from the helix structure (Fig. S5 a)). 217 
The time evolution of the root mean square deviation (RMSD) is shown for the 11 structures 218 
in Fig. 6, S8, and S9. 219 
From the initial steep increase in RMSD, it is evident that the oligomers rearrange to some 220 
extend within the first 6 ns. Furthermore, Fig. 6, S8, and S9 show that the RMSD converges 221 
for the hexamer, AA6_3ud, heptamer, AA7_1ud, AA8_4udp, AA8_4uds, AA8_FAout, and 222 
AA7_glp1 conformations. These structures appear to be stable when it comes to the overall 223 
movement of the systems. The octamer, AA6_3ud, AA6_FAout, and AA7_FAout does, 224 
however, not converge. Furthermore, the three hexameric systems and AA7_FAout present a 225 
significantly higher RMSD value compared to the other systems. 226 
To further monitor the movement of the monomers, the 2D positions of the α-carbon in the 227 
FA-Lys linker (Fig. S11) for all 11 oligomer conformations, projected onto the yz plane (the 228 
monomers are translated and rotated around the x-axis), are shown as a function of simulation 229 
time in Fig. 7, Fig. 8Fig. 9. 230 
From Fig. 7, we can conclude that the spread of the hexamer is larger than for the heptamer 231 
and the octamer throughout the simulation. Furthermore, the hexamer is squeezed to give a 232 
more flattened shape. Whereas, for the octamer it appears that the elliptical structure is 233 
unstable since one monomer appears to migrate from the oligomeric structure. In the case of 234 
the heptamer, Fig. 7 b), it is evident that the position of the α-carbon is rather dense 235 
throughout the simulation and that the structure resembles an ellipse. 236 
Fig. 8 a) shows that the AA6_3ud structure flattens drastically which corresponds to the more 237 
open structure seen in Fig. S4 a). The AA8_4udp structure maintains a more elliptical 238 
arrangement, even though one monomer seems to be leaving the structure (indicated by the 239 
circumference). The AA8_4uds structure presents a lot of movement and gains a squared 240 
shape. The AA7_1ud structure is, like the hexamer in Fig. 7 a), squeezed so that the elliptical 241 
structure is destroyed. 242 
In AA7_glp1, Fig. 9 d), monomers are more mobile than compared with the other structures 243 
resulting in a disordered (unstable) structure. In Fig. 9 b), the AA7_FAout structure appears to 244 
maintain an elliptical structure, but the movement of the α-carbons is not very spread out. Fig. 245 
9 c) shows that the α-carbon movement of the AA8_FAout system is rather centered on the 246 
starting position throughout the simulation, which indicates a stable system. However, as 247 
seen for the octamer and AA8_4udp systems, one monomer escapes from the elliptical 248 
arrangement. The AA6_FAout system (Fig. 9 a)) moves significantly throughout the 249 
simulation and this movement results in a flattened structure.  250 
 251 
Mean energy calculations based on the structures taken at every 50 ps throughout the 252 
simulations are given in Table 3. The energies calculated for the oligomeric system (peptide-253 
peptide, P-P) and the oligomer-water interactions (P-W) are normalized to the number of 254 
monomers in each oligomer to make comparison of the different systems possible. From 255 
these, it can be seen that the total P-P van der Waals (vdW) energy for the heptamer is lower 256 
than for any of the other oligomers. Considering the P-W interactions, the energy for the 257 
heptamer system is less negative than found for the other systems. In general, all the 258 
hexameric systems of liraglutide (hexamer, AA6_3ud, AA6_FAout) are higher in P-P vdW 259 
energy which might indicate that these structures are less stable than the hepta-, and 260 
octameric liraglutide oligomers. The energies show relatively large fluctuations (data not 261 
shown) which is also reflected by the relatively large standard deviations. This indicates that 262 
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internally the 11 oligomeric systems are flexible structures. 263 
Table 3: Mean energies and corresponding standard error of the mean (for P-P and P-W) and standard 
deviation (for S-S) for the 11 systems are calculated for the simulations. Van der Waals (vdW) 
energies for the peptide-peptide (P-P), peptide-water (P-W), segment-segment (seg-seg) with FA pairs 
(S-S FA), seg-seg without FA pairs interacting (S-S), and - for the heptamer – seg-seg interactions for 
the monomer pairs including the monomer with the FA pointing outward (S-S FA out) are calculated. 
Energies are also calculated for the systems where all FA chains are pointing outward (S-S all FA out). 
The energies for the P-P and P-W interactions are normalized according to the number of monomers 
in the structure. MDEnergy from NAMD was used to calculate the energies in intervals of 50 ps for 
the simulations. 
Structure P-P vdW (kcal/mol) 
P-W vdW 
(kcal/mol) 
S-S vdW 
(kcal/mol) 
S-S FA vdW 
(kcal/mol) 
S-S FA out 
vdW 
(kcal/mol) 
Hexamer -188 ± 18.9 -84.7 ± 21.1 -20 ± 4.5 -44 ± 6.1 - 
Heptamer - 200 ± 14.8 -68.1 ± 19.3 -37 ± 5.6 -56 ± 4.7 -23 ± 3.8 
Octamer -187 ± 13.7 -84.4 ± 18.0 -21 ± 3.8 -62 ± 4.1 - 
AA6_3ud -185 ± 16.4 -88.1 ± 22.1 -4.6 ± 2.2 -52 ± 7.1 - 
AA7_1ud -191 ± 19.8 -83.0 ± 22.4 -12 ± 4.6 -50 ± 4.7 -38 ± 4.8 
AA8_4udp -189 ± 15.1 -86.8 ± 18.9 -18 ± 3.1 -55 ± 3.5 - 
AA8_4uds -190 ± 16.5 -85.3 ± 21.1 -24 ± 3.6 -54 ± 4.4 - 
AA7_glp1 -160 ± 15.1 -84.9 ± 19.0 -23 ± 5.1 -26 ± 5.0 -29 ± 5.2 
Structure P-P vdW (kcal/mol) 
P-W vdW 
(kcal/mol) S-S all FA out vdW (kcal/mol)  
AA6_FAout -171 ± 13.4 -104 ± 21.5 -23 ± 3.0 
AA7_FAout -187 ± 18.9 -86.5 ± 25.3 -33 ± 3.0 
AA8_FAout -176 ± 13.1 -98.6 ± 22.8 -35 ± 3.0 
 264 
The analyses were done for segment-segment interactions where FA chains are facing each 265 
other (S-S FA), no FA chains are between them (S-S), one FA chain pointing outward (S-S 266 
FA out), and all FA chains pointing outward (S-S all FA out). See Fig. 10 and Fig. 2 for 267 
illustration of S-S, S-S FA, S-S FA out, and S-S all FA out (AA6/7/8_FAout structures), 268 
respectively. The two last analyses were only done for the heptamer, AA7_1ud, and for the 269 
AA6_FAout, AA7_FAout, and AA8_FAout oligomers since these were the only 270 
conformations relevant for such investigation. Results for the AA7_glp1 structure are 271 
reported as those for the heptamer even though it does not have any FA chains attached, since 272 
the monomers in the AA7_glp1 structure are rotated the same way as those in the heptamer 273 
with paired FA chains. It can be seen that for the structures with FA pairs, the energies are 274 
significantly lower for the monomer pairs that have FA chains facing each other, than those 275 
where no FA chains are between them. This supports the view that interactions of the FA 276 
chains contribute to the stabilization of the oligomers of liraglutide (2, 5).   277 
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DISCUSSION 278 
The experimental SAXS curves (Fig. 3) show that even at the lowest measured concentration 279 
of 1 mg/mL, repulsive interactions between liraglutide oligomers are present which increases 280 
with increasing concentration. Repulsive interactions can lead to an underestimation of the 281 
molecular weight. The SAXS data suggest that the solution structure of liraglutide is a hexa-, 282 
hepta-, or octamer. The uncertainty arises from uncertainties related to the measured 283 
concentration and the estimated partial specific volume (v) (and hence the number of 284 
monomers in the oligomer). To our knowledge, there is no value of ν for liraglutide available 285 
in literature. In this study, v = 0.73 cm3/g (corresponding to an average value for pure 286 
proteins) was used. The FA chain could contribute to an increase in the partial specific 287 
volume, but to which extent is difficult to estimate. Using v = 0.74 cm3/g as also reported in 288 
literature (48), the molecular weight increases to that resembling an octamer. From the SAXS 289 
measurements, it can only be concluded that the solution structure of liraglutide is an 290 
oligomer of approximately heptameric molecular size, with a consistent shape of an elliptical 291 
cylinder, and that this oligomerization is concentration-independent within the measured 292 
range. 293 
The MALS results indicate a hexameric solution structure of liraglutide. In contrast to the 294 
SAXS data, no repulsion interactions between oligomers were observed in the concentration 295 
range of 0.012-0.036 mg/mL. Note that the SAXS data were measured in the concentration 296 
range of 1.0-4.7 mg/mL where 1 mg/mL corresponds to the lowest concentration that can be 297 
measured. 298 
 299 
Simulation results suggest that the hexamer is an unfavorable arrangement for the monomers 300 
as seen from the structural deviation of the oligomers, given by the RMSD (Fig. 6) and the 301 
2D plot of the α-carbon in the FA-Lys linker (Fig. 7). However, the packing of the structure 302 
is relatively tight with a low SASA (Fig. 5) which indicates that more interactions are 303 
obtainable. This is also supported by the relatively low P-P energy of the hexameric system 304 
compared to the others (Table 3). The heptamer seems to present a very favorable 305 
arrangement with a tight packing indicated by the low SASA (Fig. 5), little displacement 306 
given by the low and converging RMSD (Fig. 6), and the overall elliptical shape seen in the 307 
2D plot of the α-carbon in the FA-Lys linker (Fig. 7). This is also the structure with the 308 
overall lowest P-P energy of ~ -200 kcal/mol. The octamer, like the hexamer, also appears to 309 
present an unfavorable arrangement with a slight opening and disintegration of the elliptical 310 
structure as seen in the end structure (Fig. S3), the 2D plot of the α-carbon (Fig. 7), and the 311 
high SASA (Fig. 5). The AA6_3ud presents the worst monomer arrangement out of the 11 312 
investigated structures based on the end structure (Fig. S4) that opens completely resulting in 313 
an unstable conformation as also seen from the relatively large SASA (Fig. S6), increasing 314 
RMSD (Fig. S8), and the scattered α-carbon position (Fig. 7). The AA7_1ud, AA8_4udp, and 315 
AA8_4uds systems all maintain a relatively well arranged end structure (Fig. S4) even though 316 
one monomer appears to be leaving the general elliptical structure of AA8_4up. In contrast to 317 
this, the overall packing of the three systems is relatively tight (Fig. S6), but the overall 318 
movement is scattered and very spread out as seen in the 2D plot of the α-carbon (Fig. 8). 319 
Thus, it seems like interactions between the C- and N-termini are not contributing to the 320 
energy, hence, liraglutide is most likely not to arrange like the flipped structures (AA6_3ud, 321 
AA7_1ud, AA8_4udp, and AA8_4uds). The AA6/7/8_FAout structures also present 322 
unfavorable arrangements of the monomers as can be seen by the large scattering of the 323 
individual monomers in the 2D plot of the α-carbon (Fig. 9) and large overall displacement 324 
represented by the RMSD (Fig. S9). The most important analysis result for these structures is, 325 
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however, that the S-S all FAout energies for all three systems are less negative than those of 326 
the segment interactions in systems where the FA chains are pointing towards each other 327 
(Table 3). This amplifies the hypothesis of liraglutide oligomer structures that give rise to FA 328 
interactions. However, when the FA chains are pointing outward they could, in theory, wrap 329 
around the elliptical structure in such a manner that they interact, but this appears not to be 330 
the case based on the energy calculations (Table 3) and the fact that all the FA chains in all 331 
the three structures seem to be randomly laying on the surface of the oligomers (Fig. S5) that 332 
could promote clustering of oligomers. However, this is not the case since SAXS and MALS 333 
data indicate the presence of one defined oligomeric species. The AA7_glp1 was made as a 334 
reference structure when considering the role of the FA chains. The results show that the 335 
movement of the individual monomers of this system (Fig. 9) is rather large. This emphasizes 336 
the stabilization effect of the FA chains. The system seems to have a tight packing (Fig. S7), 337 
however, this fact is more likely to be a result of the missing FA chains in the structure, and 338 
hence, less surface area. The S-S energies bear witness of a great lack in possible interactions 339 
since these energies are significantly less negative (~ -29 kcal/mol) than for those systems 340 
with FA chains present (S-S FA average energy ~ -54 kcal/mol). This corresponds well with 341 
the hydrophobic/hydrophilic areas of the monomer shown in Fig. 10 where it is evident that 342 
there is a difference in the hydrophobicity around the monomeric structure. All in all, it 343 
shows that the FA chains are important in stabilizing the liraglutide oligomer. 344 
 345 
It thus appears that the heptamer is the most favorable arrangement, which is further 346 
supported by the comparison between the experimentally determined SAXS (SAXSexp) curve 347 
and curves extracted from the simulations. The theoretical SAXS (SAXScomp) curves along 348 
with the experimentally determined curve are shown in Fig. S10. SAXScomp curves were 349 
calculated from the last structure of the 11 simulations.  350 
The discrepancies (χ2 values) for the 11 curves compared to the experimentally obtained 351 
SAXS curve are, together with the radii of gyration, given in Table S1. Besides the radius of 352 
gyration for the octamer, the radii of the systems lie very close to those found from the 353 
experimental data seen in Table 2. Also, the discrepancies given in Table S1 does not present 354 
one specific candidate with the best fit, as several of the systems have low discrepancies 355 
between their end structures and the experimentally obtained data. 356 
 357 
To clarify the best fit further, we show the time evolution of the discrepancies between 358 
SAXScomp and SAXSexp for the 11 oligomers in Fig. 11. 359 
The discrepancy of the heptamer is rather stable and low throughout the simulation. So is χ2 360 
of the hexamer, AA8_4udp, AA8_4uds, and the AA7_glp1 systems. On the contrary, the 361 
discrepancy of the octamer and AA6_3ud is very high, and increases with simulation time. 362 
That of the AA6_FAout, AA7_FAout, and AA8_FAout systems and AA7_1ud fluctuates 363 
significantly throughout the simulations. The results show that the global structure and size 364 
seems to be correct, especially for the heptamer and hexamer, but none of our simulated 365 
structures capture the precise shape of SAXSexp. 366 
Summarizing and combining all the results (see Table 4 for a combined scoring chart), it 367 
appears that the most likely solution structure of liraglutide is a heptamer where the 368 
monomers are orientated in such a way so that the attached FA chains can interact in three 369 
pairs in the direction of the elliptical arrangement and with the remaining monomer oriented 370 
so that the FA chain is pointing out. 371 
13 
 
Table 4: Scoring chart of the 11 oligomeric systems. Each system is evaluated compared to each other 
in each of the 7 categories; lowest and most stable SASA, lowest and most stable RMSD, most stable 
2D projection and elliptical shape, lowest P-P vdW energy, highest P-W vdW energy, lowest 
discrepancy from measured SAXS curve taken for the end structure, and lowest mean and standard 
deviation of the discrepancy throughout the simulation (data taken from Fig. 11). The SASA, RMSD, 
and 2D projection plots are inspected visually. 1 is the best score and 11 is the worst. The total score 
is normalized. 
Structure SASA RMSD 2D 
projection 
Energy SAXS Total 
score P-P 
vdW 
P-W 
vdW 
χ
2
 value χ2 value 
fluctuation 
Hexamer 2 8 3 5 5 7 4 4.9 
Heptamer 1 4 1 1 1 3 2 1.9 
Octamer 7 10 6 6 3 11 10 7.6 
AA6_3ud 10 11 11 8 9 10 11 10 
AA7_1ud 4 5 10 2 2 6 7 5.1 
AA8_4udp 6 3 5 3 8 5 6 5.1 
AA8_4uds 5 2 8 4 7 4 3 4.7 
AA6_FAout 11 9 2 10 11 2 8 7.6 
AA7_FAout 8 7 9 7 4 9 9 7.6 
AA8_FAout 9 1 4 9 10 1 5 5.6 
AA7_glp1 3 6 7 11 6 8 1 6.0 
 372 
The heptamer, with the above mentioned conformation, presents the best model with a total 373 
score of 1.9 being the best scoring structure in 4 out of 7 categories and landing either a 374 
second, third or fourth place in the remaining categories. It presents the best energy 375 
interactions as well as the least structural deviation of the monomers and highest packing. 376 
The hexamer presents the second best solution, but does not score best in any category. The 377 
AA6_3ud structure presents the worst arrangement of the monomers with a total score of 10. 378 
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CONCLUSION  379 
From a pharmaceutical perspective, it is important to know the oligomerization state of 380 
liraglutide with respect to stability, since uncontrolled and extensive oligomerization can 381 
drive fibrillation. Furthermore, oligomerization is important for stabilization of the 382 
formulation, which has a 2 year shelf-life in liquid form. Furthermore, MALS provides 383 
information about the mass, and SAXS provides information on mass, radius of gyration and 384 
shape. In order to get further insight in the solution structure of liraglutide, we have 385 
performed molecular dynamics simulations. The SAXS curves indicate that liraglutide 386 
undergoes concentration-independent oligomerization. Depending on the partial specific 387 
volume used for deducing the molecular weight and in turn the number of monomers in an 388 
oligomer, liraglutide may form hexa-, hepta- or octamers in solution. In contrast, the MALS 389 
results suggest that liraglutide forms hexamers in solution. The experimental results are not 390 
conclusive with respect to the size of the oligomers. Furthermore, no information can be 391 
deduced from these measurements regarding the orientation and stabilizing role of the acyl 392 
chains in the oligomers. 393 
We, therefore, performed molecular dynamics simulations on several oligomeric sets 394 
consisting of hexa-, hepta-, and octamers. Our simulation results indicate that interactions 395 
between the FA chains contribute to the stabilization of the structure and that the heptamer 396 
presents the best representation of the investigated liraglutide oligomer. Furthermore, 397 
comparing the experimentally determined SAXS curve with the SAXS curves determined 398 
from the structures extracted from the simulations shows qualitative agreement for the overall 399 
size and shape. This indicates that liraglutide in solution is most likely to form heptamers in a 400 
hollow, water-filled, elliptical cylindrical shaped structure where the monomers are orientated 401 
in such a way so that FA chains can interact pairwise. However, from the simulations, we 402 
presently are not able to identify the absolute position of the FA chains in the heptamer, but it 403 
is clear that interactions between them are significant. 404 
  405 
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FIGURE TITLES AND LEGENDS 571 
Fig. 1: Amino acid sequence of liraglutide. 
Fig. 2: Representation of the start structures for the 11 oligomeric structures. All structures are shown 
from a top view. The red line represents the orientation of the FA chain on each monomer, and the 
ellipses reflect the size and shape of the oligomers. 
Fig. 3: Scattering curves normalized for concentration. Plots at concentrations 1, 2, and 4.7 mg/mL. 
Inset shows scattering over entire measured scattering  range. Lir = liraglutide. 
Fig. 4: AF4-UV-MALS analysis of undiluted Victoza® (6 mg/mL liraglutide) and 10× diluted 
Victoza® (F10). Different injection volumes were tested. All analyses showed a single peak in the 
UV chromatogram and a uniform molar mass of around 22 kDa across the peak (left). No other peaks 
were observed in the chromatogram. The liraglutide concentration in the eluate passing the UV 
detector is shown in the right graph. 
Fig. 5: Solvent Accessible Surface Area (SASA) as a function of time for the hexamer, heptamer, and 
octamer. The area has been normalized according to the number of monomers. SASA was calculated 
every 50 ps along the trajectory using a van der Waals radius of 1.4 Å. 
Fig. 6: RMSD of the entire oligomeric structure for the hexa-, hepta-, and octamer. Structures were 
aligned to the first frame (t = 0) and deviations are determined for the backbone chains. 
Fig. 7: Position of α-carbon in the FA-Lys linker of the hexamer, a), heptamer, b), and octamer, c), as 
a function of simulation time. One monomer is highlighted by a circle in the octamer, c), to indicate 
the possible disintegration of this structure. Coordinates taken from the first 15 ns, 5 ns in the middle 
of the simulation, and the last ~5 ns are shown. The circles and dashed lines indicate the average 
structure within the 5 ns intervals shown by the dots. The yz α-carbon atom coordinates for the FA-
Lys linker were plotted in intervals of 50 ps. 
Fig. 8: Position of α-carbon in the FA-Lys linker of the AA6_3ud, a), AA7_1ud, b), AA8_4udp, c), 
and AA8_4uds d), as a function of simulation time. One monomer is highlighted in a circumference in 
AA8_4udp, c), to indicate the possible disintegration of the AA8_4udp system. See figure caption Fig. 
7 for details. 
Fig. 9: Position of α-carbon in the FA-Lys linker of the AA6_FAout, a), AA7_FAout, b), AA8_FAout, 
c), and AA7_glp1 d), as a function of simulation time. See figure caption Fig. 7 for details. 
Fig. 10: A surface plot of the liraglutide monomer showing the seg-seg orientations. The 
hydrophobicity is given in green and grey (hydrophobic) and orange (hydrophilic). The FA chain is 
colored in gray. a) shows the different hydrophobicity on either side of the monomer. 
Fig. 11: Discrepancies of the calculated SAXScomp curves and that of liraglutide as a function of 
simulation time, calculated every 5 ns. The arrows indicate that the χ2 values continuously increase 
with simulation time. 
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